Brookline Capital Acquisition in an 8-K filing said its sponsor has deposited another $167,032.54 into the SPAC’s trust for the second month of a deadline extension good until Nov. 2. The same amount had been deposited in May.
Redemptions ahead of the shareholder vote on the extension last month erased 12% of Brookline’s trust.
Brookline has a merger deal with Apexigen, a clinical-stage biopharmaceutical company. That deal was valued at $205 million before taking into account the redemptions in May. Read more.
